CEACAM5 and neoplasm: In the first step of Phase II, two criteria are used to assess the extent of locoregional disease and metastasis spread: tumor markers (CEA, CA 19-9) and imaging findings (CT of the abdomen/thorax and, if necessary, chest X-ray).